HIV/AIDS Latest News Archive
Adopting suitable protocols for the early diagnosis of STIs is necessary to allow implementation of prevention measures that will safeguard public health.
When hepatitis C is acquired in patients with HIV infection, CD4 T-cell counts temporarily decline after HCV seroconversion.
GlycA levels are higher in men with HIV compared with men with do not have HIV.
The delivery of STI/HIV screening results via SMS is well accepted but does not suit all patients.
Rectal douches could be a viable option to deliver HIV-protective drugs to men who practice receptive anal intercourse with other men.
Similar measles seroprevalence found across PLWHIV and people who do not have HIV, suggesting that PLWHIV do not need an additional dose of a measles vaccine.
Dual-class pretreatment drug resistance to first-line tenofovir/emtricitabine/efavirenz regiment may be associated with poorer virologic suppression.
Individuals with HIV and chronic pain may have greater temporal summation of pain compared with healthy individuals or those with HIV but no chronic pain.
Since the first clinical observation of HIV/AIDS in 1981, some 35.4 million people have died from AIDS-related illnesses.
Investigators evaluated the safety and effectiveness of conventional therapy with biologic immunosuppressive drugs to treat patients with HIV infection and psoriasis.
Increased proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in people with HIV may be related to abnormal coronary endothelial function.
The FDA has approved Temixys tablets for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients weighing ≥35kg.
Men who have sex with men have an increased risk of meningococcal disease, however, this risk is under-ascertained and improved surveillance is needed.
Screening recommended for those ages 15 to 65 years, including pregnant women.
Increased cancer prevention, screening, and treatment are needed for people living with HIV both before and after an initial cancer diagnosis.
The new "F4" formulation is 4 times more concentrated than the version currently available on the market.
ART prior to becoming pregnant was linked with reduced risk for hospitalization because of infections in seronegative infants who are exposed to HIV.
Ensuring access to HIV services and harm-reduction interventions earlier could substantially reduce HIV incidence over the course of an actual outbreak.
A rapid, targeted, high-coverage rollout of HIV PrEP is associated with a decrease in HIV diagnoses among high-risk MSM.
HIV-exposed infants have high rates of congenital cytomegalovirus (cCMV) infection, and in utero HIV infection seems to be a major risk factor for cCMV.
But five-year survival was above 50 percent among HIV-infected Hispanics across HPV-related cancer types.
Family-centered pediatric advance care planning may result in fewer symptoms, less suffering.
Conflicting findings regarding the association between plasma Epstein-Barr virus load in PLWHIV and HIV-related lymphomas shows a need for assessment of who benefits from an optimal management of HIV infection and comorbidities.
A dispersible fixed-dose combination tablet formulation of abacavir/dolutegravir/lamivudine for the treatment of HIV-1 had higher bioavailability of dolutegravir compared to the nondispersible film-coated tablet.
From 2014 to 2016 there was an increase in the annual number of HIV preexposure prophylaxis (PrEP) users in the United States.
Hispanic/Latino women with HIV infection face more socioeconomic and language challenges than men, but the clinical outcomes are similar.
For children receiving , HIV-1-specific antibody levels can be useful markers for measuring viral suppression or for low residual cell-associated HIV-1 DNA levels.
For criminal justice-involved persons living with HIV, sustained retention in care decreases over time post-release.
A flexible, scalable intervention increases antiretroviral therapy and medication-assisted treatment use while reducing mortality in people who inject drugs.
Antiretroviral therapy initiation within 4 weeks of a cryptococcal meningitis diagnosis in PLWHIV appears to be associated with a higher mortality risk.
A recent meta-analysis and literature review found moderate evidence supporting an association between pain outcomes in people with HIV and several psychosocial factors.
Tenofovir diphosphate in dried blood spots was strongly associated with virologic suppression in those living with HIV on TDF-based therapies.
Exposure to abacavir is associated with an increased risk for cardiovascular disease in individuals infected with HIV.
Carotid artery plaque was predictive of mortality, with differences observed by sex and HIV serostatus.
Co-infection of HIV+ and tuberculosis (TB) may be associated with decreased neurological and neuropsychological functioning.
Lopinavir/ritonavir-based treatment may be associated with higher total cholesterol in young children.
Inspection at the VIP Spa in Albuquerque detected practices that might spread HIV or hepatitis B and C.
One patient achieved complete remission in the trial, while 5 other patients experienced partial remission.
The Aptima assay has 6-sigma performance, high concordance with the RealTime reference assay, and is user friendly and efficient, making it a good choice for laboratories that perform routine monitoring of HIV-1 viral loads.
Ibalizumab showed significant antiviral activity in patients with multidrug-resistant HIV-1 infection, advanced disease, and few other treatment options
Delstrigo is approved as a complete regimen whereas Pifeltro is to be administered in combination with other antiretrovirals.
A group-based behavioral intervention reduced the sexual risk for HIV infection and transmission by nearly 40% in young transgender women.
Patient navigation may be considered an effective strategy to enhance engagement and continuation in disease treatment among people with HIV.
Improvements seen in retention in care, CD4 counts, and viral suppression.
Lower odds of having detectable viral load for older adults and those using ISTI-based regimen
Anxiety sensitivity may explain the association between stigma and pain among people living with HIV.
Recommendations have been developed for addressing the HIV/AIDS epidemic in the African-American community.
Ibalizumab has antiviral activity among patients with multidrug resistant HIV-1 infection.
The ATLAS study enrolled 570 patients infected with HIV-1; participants were randomized to either the experimental or active comparator arms.
The FDA has approved labeling updates for Genvoya, Stribild and Tybost to include new drug-drug interaction data.
The International Antiviral Society-USA Panel has updated its recommendations for the management and prevention of HIV infection, to reflect the most current data on new treatment regimens and strategies.
In a large, geographically diverse sample of patients engaged in routine HIV primary care, past HIV appointment attendance emerged as the most powerful predictor of future attendance.
New research found low and highly variable rates of HIV and syphilis screening among adolescents with pelvic inflammatory disease.
Close to one-third of sexually active HIV-positive men who have sex with men (MSM) have not received syphilis screening in the past 12 months.
A new theoretical model of understanding (PrEP) use intention in MSM highlights the complexity of decision-making about PrEP in MSM while providing insights into strategies for effective intervention.
Ritonavir-boosted protease inhibitor therapy is associated with worse outcomes, including death, in patients with HIV and heart failure.
Alcohol use may be associated with microstructural compromise to frontal white matter in patients infected with HIV who do not have dementia and are undergoing antiretroviral therapy.
ART recommended for almost all HIV-infected; should be initiated as soon as possible post diagnosis.
The SWORD 1 and SWORD 2 trials enrolled 1027 HIV-infected and virologically suppressed adults; both trials had an early (Day 1 to Week 52) and late (Week 52 to Week 148) switch phase.
In the new subgroup analysis, these results were found to be consistent regardless of baseline regimen.
Findings from the study were presented at the 22nd International AIDS Conference (AIDS 2018) in Amsterdam.
Despite CDC recommendations, about half of all heterosexual adults who are at increased risk for HIV infection and who received health care during a 12-month period were not offered HIV testing, and men were significantly less likely to be offered testing compared with women.
New HIV tests in the southern US are provided for black MSM even though they account for a substantial percentage of new diagnoses.
The Ten Questions (TQ) screen is an effective way to screen HIV-positive children for neurodevelopmental problems in resource-poor areas.
The approval of Intelence for this patient population was based on an open-label, single arm trial (N=20) which showed that the safety and efficacy of etravirine + an optimized background regimen (ritonavir-boosted protease inhibitor in combination with 1 or 2 NRTIs [N=14] and/or combination with an integrase inhibitor [N=7]) was comparable to that observed in adults.
The FDA has approved Symtuza for the treatment of HIV-1 infection in treatment-naive and in virologically suppressed adults.
Fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide might be a safe and efficacious alternative to continued boosted protease inhibitor therapy in patients with HIV-1
Mosaic adenovirus serotype 26-based vaccine induces immune responses in humans, rhesus monkeys
The fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide might provide a safe and efficacious option for ongoing treatment of HIV-1 infection
Concerns and motivations regarding living donor status in people with HIV should be assessed by physicians and independent living donor advocates.
Immediate and deferred switching from a boosted protease inhibitor to a dolutegravir regimen in HIV + patients is found to be highly efficacious.
A team of investigators sought to assess the safety and efficacy of a reduced dose of darunavir in well-suppressed, treatment-experienced individuals with HIV.
Investigators used DXA scans to assess the progression to osteopenia and osteoporosis in individuals with HIV.
Considerable numbers of MSM and persons who inject drugs who are unaware of their HIV infection report missed opportunities for diagnosis.
The researchers believe this study is the first to detect a statistically significant, unexpected inverse association between efavirenz use and depression.
Investigators sought to assess the effectiveness of tools to predict the risk of chronic kidney disease in individuals with HIV.
Appropriate monitoring and implementation of guidelines for opioid therapy is lacking in patients living with HIV.
Researchers examined unplanned pregnancies and contraceptive use among HIV-positive women in a cross-sectional study.
The final review included 47 articles that fell under 1 of the following categories: primary data on cognitive variables of providers; data on cognitive variables and perspectives of individuals at risk for HIV infection; literature on PrEP implementation; and case studies of PrEP demonstration and implementation projects.
Although rates of mother-to-child transmission of HIV have decreased as a result of effective treatments and protective delivery and feeding practices, transmission does persist.
The increased presence of social network support may decrease the risk for HIV seroconversion in black MSM.
Antiretroviral therapy resulting in long-term viral suppression of HIV may contribute to cancer prevention.
Simplification to atazanavir/ritonavir plus lamivudine as a maintenance therapy has the same effect on markers of systemic inflammation biomarkers as triple therapy.
For gay and bisexual men, an increase in HIV PrEP is associated with a reduction in condom use.
The maximum concentration of the integrase inhibitor dolutegravir was significantly higher in older people living with HIV.
The labeling now states that Prezcobix is not recommended for use in pregnant women due to substantially lower exposures of the active ingredients, darunavir and cobicistat, during pregnancy.
An increased risk for cardiovascular disease with ritonavir-boosted darunavir regimens for HIV was identified in a prospective multicenter study.
Cancer treatment rates for HIV-infected seniors were lowest among the younger subset of patients, who would likely benefit most from treatment in terms of life expectancy.
A substantial proportion of these individuals diagnosed with HIV, psychiatric disorders, and substance use disorders are out of care and urgently require intervention.
Bilirubin appeared to be inversely associated with cardiovascular disease in individuals with HIV enrolled in the Veterans Aging Cohort Study.
Implementing initiatives to maintain Medicaid enrollment and to expedite Medicaid reenrollment and having alternate resources available in gaps are important to ensure continuous antiretroviral therapy to optimize HIV outcomes.
In this study, researchers examined the appropriateness of diagnosis and treatment of chronic obstructive pulmonary disease in individuals with and without HIV.
Research is needed to understand how to prioritize supplementation and reach new testers, to educate men about the limitations of the current self-test, and to invest in the development and evaluation of self-tests able to detect early infection.
Standard-dose efavirenz-based short cycle therapy is a viable option for virologically suppressed HIV-1-infected young people receiving first-line antiretroviral therapy with 3-monthly viral load monitoring.
The FDA has received reports of serious neural tube birth defects in babies born to women who received dolutegravir for HIV.
Steady increases in the syphilis incidence rate occurred through 2015, particularly among people with HIV who are younger, non-Hispanic/Latino, and are men who have sex with men.
The use of Truvada for PrEP in the adolescent population was based on a single-arm, open-label clinical study (ATN113) among 67 HIV-1 negative young men (aged 15 to 17 years) who have sex with men (YMSM).
The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data which demonstrated a high degree of similarity between Retacrit and its reference product.
Nivolumab and pembrolizumab can be safe and effective for patients with NSCLC and HIV.
The cancer burden among persons living with HIV is projected to shift by 2030.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Shorter Antibiotic Course Noninferior for Gram-Negative Bacteremia
- HIV Control Criteria: Overview & Expert Roundtable
- Predicative Factors for Relapse in Adult Bacterial Osteomyelitis
- Cefiderocol for the Treatment of Complicated Gram-Negative UTIs
- Dolutegravir Plus Lamivudine Promising for HIV Maintenance Therapy
- Antibiotic Use in Neonatal Settings in Need of Improvement
- Shorter Antibiotic Course Noninferior for Gram-Negative Bacteremia
- Rapid Antimicrobial Susceptibility Testing on Urine Directly Accelerates Results
- Antibiotics May Be Beneficial in Children With Prolonged Wet Cough
- Emergency Department Overcrowding Associated With Delayed Antibiotics in Patients With Sepsis
- Bacteria Bystanders Play Important Role in Antibiotic Resistance Development
- Many New Cancer Patients Unaware of Their Hepatitis Status
- Worse Outcomes in Community-Acquired Pneumonia Linked to Higher FGF21 Levels
- Bacterial Pneumonia-Complicating Influenza: Risks, Morbidity, and Mortality
- Bexsero Vaccine Has Potential for Cross-Protection Against Gonorrhea